Company Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States.
The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.
Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy.
The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye.
The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system.
The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016.
Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jun 19, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 110 |
| CEO | Edward Kaye |
Contact Details
Address: 45 Wiggins Avenue Bedford, Massachusetts 01730 United States | |
| Phone | 781 430 8200 |
| Website | stoketherapeutics.com |
Stock Details
| Ticker Symbol | STOK |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001623526 |
| CUSIP Number | 86150R107 |
| ISIN Number | US86150R1077 |
| Employer ID | 47-1144582 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Edward M. Kaye M.D., Ph.D. | Chief Executive Officer and Director |
| Dr. Adrian R. Krainer Ph.D. | Co-Founder and Independent Director |
| Dr. Barry S. Ticho FACC, M.D., Ph.D. | Chief Medical Officer |
| Isabel Aznarez Ph.D. | Co-Founder and Senior Vice President of Discovery Research |
| Thomas Edward Leggett | Chief Financial Officer |
| Eric Rojas | Head of Investor Relations |
| Jonathan Allan J.D. | Corporate Secretary and General Counsel |
| Dawn Kalmar | Chief Communications Officer |
| Joan Wood | Chief Human Resources Officer |
| Shamim Ruff M.S. | Chief Regulatory Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 5, 2024 | 10-Q | Quarterly Report |
| Nov 5, 2024 | 8-K | Current Report |
| Nov 4, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 1, 2024 | 144 | Filing |
| Oct 9, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Sep 23, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |